[1] Jain N, Roberts KG, Jabbour E, et al.Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults[J]. Blood,2017,129(5):572-581.
[2] Roberts KG, Gu Z, Payne-Turner D, et al.High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults[J]. J Clin Oncol,2017,35(4):394-401.
[3] Ge Z, Gu Y, Zhao G, et al.High CRLF2 expression associates with IKZF1 dysfunction in adult acute lymphoblastic leukemia without CRLF2 rearrangement[J]. Oncotarget,2016,7(31):49722-49732.
[4] Chen IM, Harvey RC, Mullighan CG, et al.Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study[J]. Blood,2012,119(15):3512-3522.
[5] Buitenkamp TD, Izraeli S, Zimmermann M, et al.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group[J]. Blood,2014,123(1):70-77.
[6] Shochat C, Tal N, Gryshkova V, et al.Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia[J]. Blood,2014,124(1):106-110.
[7] Shochat C, Tal N, Bandapalli OR, et al.Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias[J]. J Exp Med,2011,208(5):901-908.
[8] Tal N, Shochat C, Geron I, et al.Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia[J]. Cell Mol Life Sci,2014,71(3):365-378.
[9] Roberts KG, Li Y, Payne-Turner D, et al.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia[J]. N Engl J Med,2014,371(11):1005-1015.
[10] Tran TH, Loh ML.Ph-like acute lymphoblastic leukemia[J]. Hematology Am Soc Hematol Educ Program,2016, 2(1):561-566.
[11] Loh ML, Zhang J, Harvey RC, et al.Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project[J]. Blood,2013,121(3):485-488.
[12] Tasian SK, Teachey DT, Li Y, et al.Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia[J]. Blood,2017,129(2):177-187.
[13] Maude SL, Tasian SK, Vincent T, et al.Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia[J]. Blood,2012,120(17):3510-3518.
[14] Churchman ML, Mullighan CG.Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia[J]. Exp Hematol,2017, 46:1-8.
[15] Stadt UZ, Escherich G, Indenbirken D, et al.Rapid capture next-generation sequencing in clinical diagnostics of kinase pathway aberrations in B-cell precursor aLL[J]. Pediatr Blood Cancer,2016,63(7):1283-1286.
[16] Dörge P, Meissner B, Zimmermann M, et al.IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol[J]. Haematologica,2013,98(3):428-432.
[17] Yano M, Imamura T, Asai D, et al.Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion[J]. Br J Haematol,2015,171(5):813-817.
[18] Morak M, Attarbaschi A, Fischer S, et al.Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL[J]. Blood,2012,120(26):5134-5142.
[19] Zhao C, Khadka DB, Cho WJ.Insights into the structural features essential for JAK2 inhibition and selectivity[J]. Curr Med Chem,2016,23(13):1331-1355.
[20] Waibel M, Solomon VS, Knight DA, et al.Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors[J]. Cell Rep,2013,5(4):1047-1059.
[21] Koppikar P, Bhagwat N, Kilpivaara O, et al.Hete-rodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy[J]. Nature,2012,489(7414):155-159.
[22] Sakamoto K, Imamura T, Kanayama T, et al. Ph-like acute lymphoblastic leukemia with a novel PAX5-KIDINS220 fusion transcript[J/OL]. Genes Chromosomes Cancer,2016-11-07[2017-02-10].https://www.ncbi.nlm.nih.gov/pubmed/27870151.
[23] Marincevic-Zuniga Y, Zachariadis V, Cavelier L, et al.PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia[J]. Haematologica,2016,101(1):e20-e23.
[24] Louria-Hayon I, Frelin C, Ruston J, et al.Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling[J]. Proc Natl Acad Sci U S A,2013,110(51):20599-20604.
[25] Schwab C, Ryan SL, Chilton L, et al.EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications[J]. Blood,2016,127(18):2214-2218.
[26] Ishibashi T, Yaguchi A, Terada K, et al.Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells[J]. Exp Hematol,2016,44(3):177-188.
[27] Kobayashi K, Miyagawa N, Mitsui K, et al.TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation[J]. Pediatr Blood Cancer,2015,62(6):1058-1060.
